# Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

> **NCT04465487** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** REGN6569
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT04465487
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-05
- **Primary completion:** 2025-02-07
- **Final completion:** 2025-02-07
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04465487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04465487, "Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04465487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*